Mouse Amygdala Kindling Data for Fenfluramine and Sigma-1 Modulation Studies

Experimental data from a mouse amygdala kindling model investigating the Sigma-1 chaperone protein and antiseizure medication fenfluramine. The dataset, authored by Heidrun Potschka and last updated in April 2026, contains raw measurements for seizure thresholds, severity, duration, progression, and behavioral outcomes. Each row corresponds to a different animal, with data organized into Excel sheets by experimental procedure.

Use Cases

• Analyzing the effects of Sigma-1 positive allosteric modulator E1R on seizure thresholds and kindling acquisition.
• Evaluating the disease-modifying potential of pharmacological interventions based on seizure severity and duration metrics.
• Comparing the influence of genetic Sigma-1 deficiency versus pharmacological antagonism (NE-100) on seizure development.
• Assessing behavioral outcomes and tolerability of test compounds using open field and saccharin preference tests.

Strengths

• Data is structured by experimental procedure (e.g., genetic modulation, kindling progression, behavioral tests) for clear analysis.
• Includes raw data used to generate figures for a published study, supporting reproducibility.
• Released under a permissive CC-BY-4.0 license, allowing for broad reuse and adaptation.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain statistical methods.
• The dataset is small at 236.2 KB, indicating a limited experimental scope.

Provenance

Source

figshare

Collection Method

Data generated from controlled laboratory experiments using the mouse amygdala kindling paradigm.

Time Range

Experimental timeframe not specified in metadata.

Freshness

Last updated 2026-04-27 13:29:08; freshness should be verified.

Geography

Laboratory-based; geographic origin not specified.